Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

SPRC vs FEMY: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

FEMY Wins Head-to-Head Institutional Verdict (2–2 across 6 Pillars · 5–2 Matrix Metrics)

FEMY Overall Winner 6-Pillar Tally: SPRC 2 – 2 FEMY (2 Tie) Matrix Metrics: SPRC 2 – 5 FEMY

As of Nov 16, 2026, Femasys Inc. (FEMY) is the stronger overall head-to-head candidate over SciSparc Ltd. (SPRC) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). SPRC carries a Unified Composite Score of 49.8/100 (HOLD) at $0.33 (N/M Forward P/E, -725.2% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin).

  • Technical & Structure Timing Caution: SPRC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About SPRC vs FEMY
SPRC NASDAQ
SciSparc Ltd. Ordinary Shares
Retail-Auto Dealers & Gasoline Stations
$0.33
-6.34% 1D
Market Cap $869,843
TTM Revenue $679,000
Forward P/E N/M
Beta / 30D Vol 0.01β · 159% Vol
Unified Composite Score
49.8 / 100 HOLD
Tech 45.0 Fund 51.0 Flow 50.0 Mom 59.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -44.1%), weak momentum, RSI 15
RSI-14: 14.5 · SMA20: $0.71 · SMA50: $2.90
FEMY NASDAQ Head-to-Head Winner
Femasys Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$1.28
-9.86% 1D
Market Cap $11.9M
TTM Revenue $2.3M
Forward P/E N/M
Beta / 30D Vol 4.01β · 72% Vol
Unified Composite Score
52.6 / 100 HOLD
Tech 61.0 Fund 62.0 Flow 50.0 Mom 64.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -21.5%), weak momentum, RSI 35
RSI-14: 34.6 · SMA20: $1.43 · SMA50: $1.92

6-Pillar Scorecard Institutional Category Breakdown (SPRC 2 – 2 FEMY)

Columns: Metric · SPRC · FEMY
1. Valuation Multiples SPRC
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue 1.3x 4.9x
2. Growth & Scale FEMY
Revenue Growth (YoY) -38.4% -18.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $679,000 $2.3M
Market Cap $869,843 $11.9M
3. Profitability & Quality SPRC
Gross Margin N/A 60.9%
Operating Margin -725.2% -763.9%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -164.5% -425.0%
4. Balance Sheet & Cash Flow FEMY
Cash Generation (TTM) -$4.8M EBITDA -$19M
Cash Flow Margin N/A N/A
Net Cash / Leverage $6.79 Book/Sh · -164.5% ROE -$658,045 Net Debt (0.65x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Medical Instruments & Supplies Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: SPRC (2) vs FEMY (5)
Institutional Metric SPRC FEMY Criterion Row Edge
Market Capitalization
Scale
$869,843 $11.9M Larger Scale FEMY
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
-38.4% -18.9% Higher Growth FEMY
Operating Margin (TTM)
Profitability
-725.2% -763.9% Higher Margin SPRC
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-164.5% -425.0% Higher ROE SPRC
52-Week Range Position
Momentum
0% ($0–$16) 17% ($0–$6) Stronger Trend FEMY
Beta / 30D Volatility
Risk Regime
0.01β · 159% Vol 4.01β · 72% Vol Lower Realized Risk FEMY
Unified Institutional Score
Composite Signal
49.8 / 100 (HOLD) 52.6 / 100 (HOLD) Higher Composite FEMY
Trailing 12M Revenue (USD)
Operating Scale
$679,000 $2.3M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 60.9% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.3x EV/Rev N/M PEG · 4.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.8M EBITDA ($6.79 Book/Sh · -164.5% ROE) -$19M (-$658,045 Net Debt (0.65x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon FEMY +58.13 pp
SPRC: -80.55% · FEMY: -22.42%
3M Horizon FEMY +53.1 pp
SPRC: -94.92% · FEMY: -41.82%
6M Horizon FEMY +345.26 pp
SPRC: -92.45% · FEMY: +252.81%
1Y Horizon FEMY +141.86 pp
SPRC: -87.08% · FEMY: +54.78%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SPRC vs FEMY. Trailing 12-month operating profitability (SPRC -725.2% vs FEMY -763.9%) and valuation multiples (SPRC N/M vs FEMY N/M Forward P/E) are benchmarked directly in Pillar 4 below.

SPRC ADR TTM Benchmark FX-Normalized USD
TTM Revenue$679,000
Gross MarginN/A
Op. Margin-725.2%
ROE / Fwd P/E-164.5% · N/M
FEMY ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.3M
Gross Margin60.9%
Op. Margin-763.9%
ROE / Fwd P/E-425.0% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
SPRC UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact SPRC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
FEMY UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact FEMY Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
SPRC Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $869,843 market capitalization and -725.2% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
FEMY Moat Profile Cyclical / Execution-Driven Positioning
Medical Instruments & Supplies Operator
Competes within the Medical Instruments & Supplies value chain with $11.9M market capitalization and -763.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ SPRC vs FEMY Key Questions & Quantitative Answers

As of Nov 16, 2026, Femasys Inc. (FEMY) is the stronger overall head-to-head candidate over SciSparc Ltd. (SPRC) in the Tradestie Institutional Equity Comparison Engine, winning 5–2 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Balance Sheet & Cash Flow). SPRC carries a Unified Composite Score of 49.8/100 (HOLD) at $0.33 (N/M Forward P/E, -725.2% operating margin), whereas FEMY carries 52.6/100 (HOLD) at $1.28 (N/M Forward P/E, -763.9% operating margin). Technical & Structure Timing Caution: SPRC is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 14.5); meanwhile FEMY is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 34.6). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

FEMY leads the Growth & Scale pillar: SPRC posts -38.4% YoY revenue growth and +0.0% YoY earnings growth on $679,000 TTM revenue (N/A gross margin, -725.2% operating margin), compared with FEMY at -18.9% YoY revenue growth and +0.0% YoY earnings growth on $2.3M TTM revenue (60.9% gross margin, -763.9% operating margin). On trailing 12-month operating scale, SPRC generates $679,000 in USD-normalized revenue versus $2.3M for FEMY. In operating R&D and SG&A reinvestment, SPRC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for FEMY.

SPRC screens cheaper on headline valuation multiples. SPRC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 1.3x EV/Revenue (unreported EBITDA margin), whereas FEMY trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 4.9x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SPRC (-164.5% ROE) versus FEMY (-425.0% ROE) capital efficiency.

In options market volatility and institutional positioning, SPRC carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.01β · 159% Vol realized risk). By comparison, FEMY carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.01β · 72% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.